Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer—2020 update. Part 1: screening, diagnosis, and local treatment with curative intent
N Mottet, RCN van den Bergh, E Briers… - European urology, 2021 - Elsevier
Objective To present a summary of the 2020 version of the European Association of Urology
(EAU)-European Association of Nuclear Medicine (EANM)-European Society for …
(EAU)-European Association of Nuclear Medicine (EANM)-European Society for …
EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer—2024 update. Part I: screening, diagnosis, and local treatment with curative intent
P Cornford, RCN van den Bergh, E Briers… - European urology, 2024 - Elsevier
Abstract Background and objective The European Association of Urology (EAU)-European
Association of Nuclear Medicine (EANM)-European Society for Radiotherapy and Oncology …
Association of Nuclear Medicine (EANM)-European Society for Radiotherapy and Oncology …
Neoadjuvant hormonal therapy before radical prostatectomy in high-risk prostate cancer
G Devos, W Devlies, G De Meerleer… - Nature Reviews …, 2021 - nature.com
Patients with high-risk prostate cancer treated with curative intent are at an increased risk of
biochemical recurrence, metastatic progression and cancer-related death compared with …
biochemical recurrence, metastatic progression and cancer-related death compared with …
Remodeling tumor immune microenvironment by using polymer-lipid-manganese dioxide nanoparticles with radiation therapy to boost immune response of castration …
Despite substantial progress in the treatment of castration-resistant prostate cancer (CRPC),
including radiation therapy and immunotherapy alone or in combination, the response to …
including radiation therapy and immunotherapy alone or in combination, the response to …
[HTML][HTML] Online adaptive radiotherapy potentially reduces toxicity for high-risk prostate cancer treatment
Background and purpose With daily, MR-guided online adapted radiotherapy (MRgART) it
may be possible to reduce the PTV in pelvic RT. This study investigated the potential …
may be possible to reduce the PTV in pelvic RT. This study investigated the potential …
An eight-CircRNA assessment model for predicting biochemical recurrence in prostate cancer
S Wang, W Su, C Zhong, T Yang, W Chen… - Frontiers in Cell and …, 2020 - frontiersin.org
Prostate cancer (PCa) is a high morbidity malignancy in males, and biochemical recurrence
(BCR) may appear after the surgery. Our study is designed to build up a risk score model …
(BCR) may appear after the surgery. Our study is designed to build up a risk score model …
Identification of a 9-gene signature to enhance biochemical recurrence prediction in primary prostate cancer: a benchmarking study using ten machine learning …
Prostate cancer (PCa) is a prevalent malignancy among men worldwide, and biochemical
recurrence (BCR) after radical prostatectomy (RP) is a critical turning point commonly used …
recurrence (BCR) after radical prostatectomy (RP) is a critical turning point commonly used …
Management of patients with node-positive prostate cancer at radical prostatectomy and pelvic lymph node dissection: a systematic review
G Marra, M Valerio, I Heidegger, I Tsaur… - European urology …, 2020 - Elsevier
Context Optimal management of prostate cancer (PCa) patients with lymph node invasion at
radical prostatectomy and pelvic lymph node dissection still remains unclear. Objective To …
radical prostatectomy and pelvic lymph node dissection still remains unclear. Objective To …
Neoadjuvant novel hormonal therapy followed by prostatectomy versus up-front prostatectomy for high-risk prostate cancer: a comparative analysis
Purpose: We sought to compare outcomes between neoadjuvant therapy with a novel
hormonal agent (NHA) prior to radical prostatectomy (neo-RP) and up-front radical …
hormonal agent (NHA) prior to radical prostatectomy (neo-RP) and up-front radical …
The potential of CAR T cell therapy for prostate cancer
Chimeric antigen receptor (CAR) T cell immunotherapy involves the genetic modification of
the patient's own T cells so that they specifically recognize and destroy tumour cells …
the patient's own T cells so that they specifically recognize and destroy tumour cells …